ライフサイエンスコーパス: hematology

1 ar" OR "neurology" OR "gastrointestinal" OR "hematology".

2 Blood Institute and the American Society of Hematology.

3 lood cell which is important in the field of hematology.

4 fulness of AMPSs in point-of-care diagnostic hematology.

5 review series on the role of epigenetics in hematology.

6 potential uses of this model in experimental hematology.

7 ctions of circulating miRNAs in the field of hematology.

8 te chromatin modification patterns to normal hematology.

9 ial has been an elusive goal of experimental hematology.

10 lonality often defines the diseased state in hematology.

11 ia is an important aspect of the practice of hematology.

12 ly toward clinical practice in neurology and hematology.

13 a wide range of biologic systems, including hematology.

14 e most challenging and expensive problems in hematology.

15 quacy of dialysis, or serum biochemistry and hematology.

16 tial to revolutionize health care, including hematology.

17 cer drug approvals in oncology and malignant hematology.

18 d draws showed normal clinical chemistry and hematology.

19 to have a profound impact on health care and hematology.

20 ne cell populations that matched traditional hematology.

21 sis database maintained by the Department of Hematology.

22 International Council for Standardization in Hematology.

23 ) transcription factor family revolutionized hematology.

24 uture prospects for genome editing to impact hematology.

25 rates as defined by the American Society of Hematology.

26 new physicians to specialize in nonmalignant hematology.

27 ons that predominantly focus on nonmalignant hematology.

28 dress 'druggability' of new PPIs relevant to hematology.

29 es, coupled with principles of neurology and hematology.

30 nces in the science and clinical practice of hematology.

31 ment guidelines from the American Society of Hematology (1996) and the British Committee for Standard

32 in (1) trauma and transfusion medicine, (2) hematology, (3) maternal-fetal medicine/obstetrics, and

33 us diseases and AIDS (70%), and oncology and hematology (61.9%).

34 with risk organ involvement (liver, spleen, hematology), 68.6% of patients (35 of 51) with multisyst

35 administered without a significant impact on hematology, a potential concern for KIT inhibitors.

36 city; laboratory values (serum chemistry and hematology), according to Food and Drug Administration t

37 follow-up measures of health markers (e.g., hematology/adipose biopsies).

38 Purpose: To update American Society of Hematology/American Society of Clinical Oncology recomme

39 otypic characterization included analysis of hematology, amino acid profiles, metabolism, and sudomot

40 In support of this, hematology analysis revealed that Nrf2(-/-) mice suffer

41 Automated hematology analyzer (AHA) offers high accuracy using ven

42 Collected blood was profiled with a hematology analyzer and spleens were analyzed by whole t

43 ptured by a high-throughput peroxidase-based hematology analyzer during performance of a complete blo

44 merating AbsCD4 and CD4% and Sysmex XT-4000i hematology analyzer for determining Hb levels.

45 Calibur platform for CD4 and Sysmex XT-4000i hematology analyzer for Hb concentrations in resource-li

46 POC Hgb levels correlated with hematology analyzer Hgb levels (r = 0.864 and r = 0.856

47 varying degrees and etiologies and compared hematology analyzer Hgb levels with POC Hgb levels, whic

48 for the first time, the use of our CTV as a hematology analyzer that is able to measure MCV, MCH, me

49 The CellaVision DM96 is a digital hematology analyzer that utilizes neural networks to loc

50 and venous blood samples using the standard hematology analyzer was high, with no clinically relevan

51 were measured and compared using a standard hematology analyzer.

52 d a decent match to a commercially available hematology analyzer.

53 n accuracy > 95% as compared to an automated hematology analyzer.

54 gram, and white blood cell (WBC) counts with hematology analyzer.

55 Hematology analyzers evaluate CBCs by making high-dimens

56 Recently, several hematology analyzers have been developed to improve accu

57 Modern hematology analyzers provide additional data on the hete

58 Automated hematology analyzers were used to enumerate TNCs.

59 taken millions of times per day by clinical hematology analyzers, and they are important factors in

60 For that purpose, sophisticated automated hematology analyzers, microscopy, and bedside microfluid

61 typically measured from blood samples using hematology analyzers, which are housed in hospitals, cli

62 agreement with flow cytometry and automated hematology analyzers.

63 , and abstracts from the American Society of Hematology and American Society of Clinical Oncology pub

64 asurements of the mouse body and organ mass, hematology and biochemistry evaluation, and histopatholo

65 Hematology and blood biochemistry were unremarkable.

66 The American Society of Hematology and British Committee for Standards in Haemat

67 This review updates the American Society of Hematology and British guidelines on immune thrombocytop

68 gnostic and therapeutic insights relevant to hematology and cardiovascular medicine, and further adva

69 Length of stay; cost of care; costs of hematology and chemistry evaluation, pharmacy, and radio

70 taceans as it occurs prior to alterations in hematology and chemistry.

71 ignificant changes from baseline in selected hematology and clinical chemistry parameters.

72 Rabbits serum lipid profile, hematology and histology were investigated.

73 c exploration of single patients not only in hematology and immunology but also in other fields.

74 to learn, and cross-disciplinary studies in hematology and immunology will continue to pave the way

75 patient-centered, value-oriented approach in hematology and medical oncology.

76 our demonstration of unique applications in hematology and microbiology.

77 S 2006 trial by Nordic Society for Pediatric Hematology and Oncology (NOPHO), Dutch Childhood Oncolog

78 ccording to the Nordic Society for Pediatric Hematology and Oncology ALL2008 protocol received five i

79 ia (ALL) in Italian Association of Pediatric Hematology and Oncology Berlin-Frankfurt-Munster (AIEOP-

80 For all Medicare Advantage insurers, hematology and oncology drugs represented the largest pr

81 This Update in Hematology and Oncology features 16 articles published i

82 hone interview technique to gather data from hematology and oncology fellows.

83 rug Administration granted 176 new malignant hematology and oncology indications based on single-arm

84 he US Food and Drug Administration Office of Hematology and Oncology Products in 2015.

85 Hematology and oncology specialists who refer patients t

86 AIEOP (Italian Association of Pediatric Hematology and Oncology) performed a nationwide multicen

87 diseases and being more broadly employed in hematology and oncology, optimal management strategies o

88 eneral information relevant to the fields of hematology and oncology, was used to identify relevant R

89 y for research and training in nonneoplastic hematology and presents potential strategies for address

90 signs of excessive inflammation with normal hematology and serology for inflammatory markers three m

91 no patient did elevated HAMA titers develop, hematology and serum chemistry changes were clinically i

92 ples: to promote both the art and science of hematology and to hold a high-quality Educational Meetin

93 Clinical, hematology, and blood transfusion databases were linked

94 ory evaluations included serum biochemistry, hematology, and measurements of hemolytic antipig antibo

95 erts from the fields of immunology, allergy, hematology, and pathology contributed to this project.

96 as cancer biology, microbiology, immunology, hematology, and stem cell biology.

97 gy and hepatology, interventional radiology, hematology, and surgery.

98 f Clinical Oncology, the American Society of Hematology, and the Coalition of National Cancer Coopera

99 ty of Clinical Oncology, American Society of Hematology, and the International Myeloma Workshop.

100 hat had contributed so much to histology and hematology, and would soon contribute equally to experim

101 ia is one of the great successes of clinical hematology andoncology.

102 ents was reported at the American Society of Hematology Annual Meeting, 2012; the approach was feasib

103 collected on lipoprotein levels, hemostasis, hematology, anthropometry, blood pressure, medical histo

104 c personnel during the participants' routine hematology appointment were graded by 2 masked retina sp

105 lementation of PRO assessment in the current hematology arena, by providing some real world examples

106 linic experience, visibility of nonmalignant hematology as a career path, and level of training progr

107 tter provides a snapshot of the evolution of hematology as a scientific and clinical discipline and t

108 alty, creating tensions between oncology and hematology as each discipline defended its identity.

109 an overview of the current state of AI/ML in hematology as of 2025, identify existing gaps, and offer

110 promise may soon be realized in the field of hematology, as hematopoietic stem cell transplants are a

111 ety of Clinical Oncology/American Society of Hematology (ASCO/ASH) recommendations for the use of epo

112 The American Society of Hematology (ASH) and British Committee for Standards in

113 ng antedated that of the American Society of Hematology (ASH) by more than 11 years and Stratton and

114 thologists (CAP) and the American Society of Hematology (ASH) developed an evidence-based guideline o

115 random sample of the US American Society of Hematology (ASH) membership was surveyed.

116 In 2011, the American Society of Hematology (ASH) published updated guidelines for the ma

117 The American Society of Hematology (ASH) released its first Choosing Wisely((R))

118 The American Society of Hematology (ASH) turns 50 years old in 2008, and we have

119 he Annual Meeting of the American Society of Hematology (ASH), and financial professionals frequently

120 Members Committee of the American Society of Hematology (ASH).(1) The purpose of this initiative is t

121 ESMO and the European Hematology Association (EHA) initiated a collaboration t

122 rrow Transplantation (EBMT) and the European Hematology Association (EHA) involved an international p

123 ology congresses (ie, ASCO 2016 and European Hematology Association 2016) were added to include the m

124 th of Blood in the context of the history of hematology before 1946, emphasizing the American experie

125 from the perspectives of both hepatology and hematology beginning with a brief update on the physiolo

126 nd follow-up measures of health markers (eg, hematology/biopsies).

127 e foremost scholarly journal in the field of hematology, Blood, designed to provide its readership wi

128 col experience of bone marrow failure in the Hematology Branch of the National Heart, Lung, and Blood

129 rm the practice of both benign and malignant hematology, but clinicians must carefully consider these

130 A network of internal medicine and hematology centers across France recruited 198 incident

131 provement study was conducted at 5 pediatric hematology centers in Florida.

132 r (Lower Silesian Oncology, Pulmonology, and Hematology Centre, Wroclaw, Poland) and included adult w

133 riteria) that was conducted in an outpatient hematology clinic at a US tertiary care hospital from Se

134 otent stem cell (iPSC) technologies into the hematology clinic.

135 The 2018 American Society of Hematology clinical practice guideline on prophylaxis fo

136 sease with respect to clinical presentation, hematology, clinical microbiology, thoracic radiography,

137 ies, which are derived from patients seen in hematology clinics.

138 ectrocardiograms (ECGs); clinical chemistry, hematology, coagulation, and urinalysis; psychomotor fun

139 subjects with respect to clinical chemistry, hematology, coagulation, urinalysis, orthostatic vital s

140 roved by concerted action on the part of the hematology community of the richer countries together wi

141 n, two trials presented at two international hematology congresses (ie, ASCO 2016 and European Hemato

142 The goals of the chapter are to help the hematology consultant work through the differential diag

143 including serum protein electrophoresis and hematology consultation should be considered in the mana

144 be referred for specialized parasitic and/or hematology consultation.

145 loid leukemia (CML), the American Society of Hematology convened an expert panel to review and docume

146 linical Oncology and the American Society of Hematology developed an evidence-based clinical practice

147 applications in the fields of neuroscience, hematology, developmental biology, stem cell biology and

148 tive admissions of patients with a malignant hematology diagnosis at our institution between March 20

149 Blood chemistries and hematology did not reveal the etiology of the hemorrhage

150 The authors are in the Hematology Division of the Department of Medicine, Brigh

151 logy, pulmonology, endocrinology, neurology, hematology, emergency medicine, nursing, trialists, and

152 linary panel of medical oncology, neurology, hematology, emergency medicine, nursing, trialists, and

153 d anesthesia as well as representatives from hematology, emergency medicine, transplant surgery, and

154 e unresolved issues, the American Society of Hematology established a panel to develop a practice gui

155 ologists, reliable patient access to optimal hematology expertise, and optimal patient outcomes.

156 Despite its promise, AI implementation in hematology faces critical challenges, including bias, da

157 vices are poised to substantially impact the hematology field by providing a high-throughput and rapi

158 confirmation of A2 status of kidney donors; hematology for comprehensive typing for patients with an

159 GIM/FP/GP: [Formula: see text] Hematology: [Formula: see text] Neurology: [Formula: see

160 a: see text] Cardiology: [Formula: see text] Hematology: [Formula: see text].

161 la: see text] Neurology: [Formula: see text] Hematology: [Formula: see text].

162 GIM/FP/GP: [Formula: see text] Hematology: [Formula: see text].

163 induce the changes in serum cholesterol and hematology generally found in copper-deficient animal mo

164 toma Group and German Pediatric Oncology and Hematology Group), and Japan.

165 American Society of Hematology Harold Amos Medical Faculty Development Progr

166 The field of malignant hematology has experienced extraordinary advancements wi

167 in German Society of Pediatric Oncology and Hematology Hodgkin Lymphoma Trial 95.

168 vant fields, including allergy, dermatology, hematology, immunology, laboratory medicine, and patholo

169 which integrate the most recent knowledge in hematology, immunology, pathology, and genetics.

170 g in model organisms along with experimental hematology implicate C/EPBepsilon, RUNX1/AML1, Notch fam

171 Group in 1992 and by the American Society of Hematology in 1996.

172 uacy of dialysis, and serum biochemistry and hematology in patients dialyzed with new or reprocessed

173 and diagnostic codes, models that also used hematology indices had better discrimination and calibra

174 Models using only hematology indices had concordance index ranging from 0.

175 had some of these presenting issues and what hematology input was required.

176 The American Society of Hematology is building a collection of case studies to g

177 The field of clinical hematology is no exception.

178 tool over the past two to three decades, in hematology it has primarily been used to investigate are

179 esents an intriguing paradox in the field of hematology known as "Dameshek's riddle." Recent cancer s

180 h use in low-resource settings where central hematology laboratories are not accessible.

181 d cell counts were performed by the clinical hematology laboratory.

182 ts and outpatients who provided blood to the hematology laboratory.

183 shing high-impact RCTs (NEJM, Lancet, Lancet Hematology, Lancet Oncology, Journal of Clinical Oncolog

184 tices participating in the Florida Pediatric Hematology Learning and Action Network, 3 practices lack

185 American Society of Hematology; Leukemia and Lymphoma Society; National Canc

186 CMV-DNA, hematology, liver enzymes, neutralizing antibodies, and

187 lation against data obtained from commercial hematology machines.

188 of patients with germline predisposition to hematology malignancies and will consider applications a

189 American Society of Hematology, National Cancer Institute, Alan J Hirschfiel

190 American Society of Hematology, National Institutes of Health, Cincinnati Ch

191 ement in disease across various disciplines (hematology, nephrology, obstetrics, transplantation, rhe

192 by Dutch-Belgium Cooperative Trial Group for Hematology Oncology and the Nordic Myeloma Study Group (

193 AML Cooperative Group and the Dutch-Belgian Hematology Oncology Cooperative group).

194 bacteria, as well as with otolaryngology and hematology oncology reports addressing Turicella otitidi

195 e, Dutch-Belgian Cooperative Trial Group for Hematology Oncology, and Janssen Research & Development.

196 he Dutch-Belgian Cooperative Trial Group for Hematology Oncology, and Janssen Research and Developmen

197 he Dutch-Belgian Cooperative Trial Group for Hematology Oncology.

198 nd Dutch-Belgian Cooperative Trial Group for Hematology Oncology.

199 ders with expertise in transfusion medicine, hematology, oncology, transplantation, obstetrics, and i

200 tory syncytial virus-B (RSV-B) outbreak in a hematology-oncology and stem cell transplant unit.

201 was performed at a referral-based pediatric hematology-oncology clinic and associated inpatient serv

202 We undertook a survey of hematology-oncology fellows training at cancer centers d

203 Factors that influence hematology-oncology fellows' choice of academic medicine

204 Nearly one-third of hematology-oncology outpatients were prescribed antibiot

205 udy, which included 1272 platelet-transfused hematology-oncology patients who received 6031 prophylac

206 In hospitalized hematology-oncology patients, culture of blood drawn thr

207 also high, with rates up to 40% in both the hematology-oncology population and solid organ transplan

208 ile infection, ranging from 6% to 33% in the hematology-oncology population and up to 23% among lung

209 C. krusei was most commonly isolated from hematology-oncology services, where only 76.7% of isolat

210 The inclusion of step-down units and general hematology-oncology units in adult 2017 baseline SAAR mo

211 urvey study invited members of the Pediatric Hematology-Oncology Vascular Anomalies Interest Group, r

212 2009, 4 immunocompromised patients within a hematology-oncology ward exhibited symptoms of pH1N1 inf

213 vened an Expert Panel of medical, radiation, hematology-oncology, oncology nursing, palliative care,

214 treatment, and prevention of C. difficile in hematology-oncology, solid organ transplant, and HIV-inf

215 s (Dutch-Belgian Cooperative Trial Group for Hematology/Oncology [HOVON], UK Medical Research Council

216 tional risk factor challenges specialists in hematology/oncology and cardiovascular medicine alike.

217 convened with representation from pediatric hematology/oncology and HSCT, pediatric infectious disea

218 convened with representation from pediatric hematology/oncology and HSCT, pediatric infectious disea

219 disciplinary team with expertise not only in hematology/oncology but also in neurology, neuroradiolog

220 4 HCV infections among patients at the same hematology/oncology clinic.

221 otexafin gadolinium is currently in numerous hematology/oncology clinical trials for use as a single

222 ubjects were advanced cancer patients in the Hematology/Oncology Clinics at the University of Chicago

223 care in outpatient care facilities, such as hematology/oncology clinics.

224 out 18% of immunosuppressed thrombocytopenic hematology/oncology patients and represents a significan

225 ignificant problem for many thrombocytopenic hematology/oncology patients in spite of platelet transf

226 Academic divisions of hematology/oncology seem to have difficulty recruiting a

227 A survey of directors of adult and pediatric hematology/oncology subspecialty training programs in th

228 ent cohort study of patients admitted to our hematology/oncology unit, surveillance cultures revealed

229 tional lymphoma experts representing medical hematology/oncology, radiology, radiation oncology, and

230 RT era, EORTC criteria, developed for use in hematology/oncology, still applied to only half the case

231 atric subspecialty programs in hematology or hematology/oncology.

232 e no significant changes in QoL scores or in hematology or clinical chemistry among treatment groups.

233 There were no changes in hematology or clinical chemistry parameters.

234 nd 47% of pediatric subspecialty programs in hematology or hematology/oncology.

235 ans who were board-certified or -eligible in hematology or medical, pediatric, and gynecologic oncolo

236 y nonendocrinology specialties (eg, oncology/hematology; OR, 3.43; 95% CI, 2.47-4.76), and orders not

237 ges were found in any clinical chemistry and hematology parameters measured.

238 Clinical chemistry and hematology parameters were determined from terminal bloo

239 samples, and 419 serum samples obtained from hematology patients according to the recommendations.

240 is of a prospective cohort of critically ill hematology patients admitted to 17 ICUs.

241 This study screened for mutations in 322 hematology patients classified according to IA status an

242 ius polymerase chain reaction (PCR) assay in hematology patients from 12 centers.

243 and serum samples concurrently obtained from hematology patients in a multicenter retrospective anony

244 nce of the serum galactomannan (GM) assay in hematology patients with a potentially low pretest risk

245 prove helpful for the risk stratification of hematology patients with ARF.

246 Survival in critically ill oncology and hematology patients with sepsis improved significantly o

247 Hematology patients with this opportunistic infection re

248 19V infection can be a serious infection for hematology patients with underlying hemolysis or comprom

249 Sites of infection were lungs (28%; 79% in hematology patients), rhinocerebral (25%; 64% in diabeti

250 ently available monotherapy, particularly in hematology patients, has stimulated interest in studying

251 CR assay with blood specimens from high-risk hematology patients.

252 tiplex PCR assay is common in critically ill hematology patients.

253 due to the high rate of viral shedding among hematology patients.

254 The incidence of IA in high-risk hematology populations is relatively low (<10%), despite

255 areas in which COVID-19 has implications for hematology practice.

256 h timely reviews, expert opinion on clinical hematology, practice-changing clinical trials, and insig

257 Among 5 pediatric hematology practices participating in the Florida Pediat

258 gift donation from Jack Levin to the Benign Hematology programme at Yale, and the National Institute

259 izations, including the American Society for Hematology provide general recommendations, individual c

260 In 1996 the American Society of Hematology published a landmark guidance paper designed

261 In 1996, the American Society of Hematology published a practice guideline for immune thr

262 ICU, related to five groups (cardiovascular, hematology, pulmonary, renal, and endocrine).

263 divided into nine subgroups: cardiovascular, hematology, pulmonary, renal, endocrine and nutrition, g

264 rarely performed, and no ethnicity-specific hematology reference intervals have been reported yet.

265 y calculated daily, which was visible to the hematology research team for patients in the interventio

266 Although imaging is a vital tool in hematology research, the 3-dimensional architecture of t

267 ntithrombotic therapy and a valuable tool in hematology research.

268 The histopathology and hematology results do not show any toxicity to major per

269 reciable differences in disease progression, hematology, serum biochemistry, virus titers, or lethali

270 fety analyses included physical examination, hematology, serum chemistry, urinalysis, antibody titers

271 tatic management of individual patients, the hematology service must be involved in setting hospital

272 ing safe opioid prescribing practices in the hematology setting.

273 mponent, MPC), was measured by the Advia 120 Hematology System as a marker surrogate of platelet acti

274 history, blood analysis using chemistry and hematology tests, and demographic data were collected.

275 olic acid package inserts, early editions of hematology textbooks, and international expert reports p

276 In hematology, the clinical disease of mastocytosis is char

277 ments of a new research agenda for geriatric hematology: the exchange of age limits for rigorous frai

278 they have entered common use in experimental hematology to investigate genetic function.

279 ministration invited the American Society of Hematology to participate in the organization and conduc

280 Hematology topics include the use of dabigatran, anticoa

281 The following grade >= 3 hematology toxicities were more frequent in the CE+V arm

282 Hematology trials were not evaluated by ESMO-MCBS.

283 luenza A(H1N1) 2009 virus that occurred in a hematology unit in the United Kingdom.

284 Hospitalization in a pediatric hematology unit may represent initial exposure to BKPyV

285 rent types of health care settings, except a hematology unit, have been reported.

286 DNAemia over a 3-year period in a pediatric hematology unit.

287 Serum chemistries, hematology, urinalysis, gastrointestinal complications,

288 ficiency at one institution and describe the hematology, virology, and cytokine findings.

289 ic millimeter) who were being treated on the hematology ward or in the intensive care unit to receive

290 ycin-resistant enterococci transmission in a hematology ward.

291 We conducted a 6-month survey on 2 hematology wards at Addenbrooke's Hospital, Cambridge, U

292 Hematology was analyzed in venous blood samples.

293 Hematology was consulted and investigations led to diagn

294 duction ratios, monthly blood chemistry, and hematology were also studied during the 12-wk period.

295 sumption, fecal corticosterone and blood for hematology were collected.

296 Growth and hematology were not affected significantly by iron-zinc

297 Subjects' serum biochemistry and hematology were recorded at screening and at 24-hour fol

298 tering clinical and scientific excellence in hematology will continue as the Society's raison d'etre.

299 This paper, by one of the legends of hematology, William Dameshek, and his colleague Edward M

300 nical development of demethylating agents in hematology, with a focus on azacitidine and decitabine.